tranexamic acid

(redirected from Lysteda)
Also found in: Encyclopedia.

tranexamic acid

 [tran″ek-sam´ik]
an agent that combats fibrinolysis by competitively inhibiting activation of plasminogen; used in prophylaxis and treatment of hemorrhage associated with excessive fibrinolysis, such as that following oral surgery in patients with hemophilia; administered orally or intravenously.

tran·ex·am·ic ac·id

(tran'eks-am'ik as'id),
A competitive inhibitor of plasminogen activation and of plasmin; used in hemophilia to reduce or prevent hemorrhage.

tranexamic acid

A drug that interferes with the dissolution of blood clot (fibrinolysis) and can be used to prevent bleeding during minor operations such as tooth extraction in people with HAEMOPHILIA. A brand name is Cyklokapron.
References in periodicals archive ?
The company added the tranexamic acid tablets are the generic equivalent to Ferring Pharmaceuticals' Lysteda.
Effective immediately, Watson plans to begin shipping the generic Lysteda tablets, which is indicated for the treatment of cyclic heavy menstrual bleeding.
In November 2010, the FDA approved the 3.9-g/day dosage of Lysteda to treat heavy menstrual bleeding based on results from the pivotal trials (Obstet.
Lysteda is a nonhormonal lysine analog that acts as a competitive plasmin inhibitor; it is not a contraceptive.
Xanodyne Pharmaceuticals (which manufactured Lysteda) and Ferring Pharmaceuticals (its current owner) were major sponsors of this study.
The oral formulation was approved by the Food and Drug Administration late last year for the treatment of cyclic heavy menstrual bleeding and is marketed under the trade name Lysteda. It's a valuable alternative to surgical or hormonal treatments for this disorder, which affects up to 22 million Americans, said Dr.
Very soon an additional option will be available--the antifibrinolytic agent tranexamic acid (to be sold by Ferring Pharmaceuticals under the brand name Lysteda).
The FDA has approved Lysteda, an oral form of tranexamic acid, for the treatment of menorrhagia.
It is Ferring's second major investment in the therapeutic field in two years, having purchased the global marketing rights for LYSTEDA (tranexamic acid) for the treatment of heavy menstrual bleeding, in May 2010.
Disclosures: The study was funded by Xanodyne Pharmaceuticals and Ferring Pharmaceuticals, which acquired global marketing rights to Lysteda last May.
The Food and Drug Administration approved Lysteda, a proprietary form of tranexamic acid, for the treatment of menorrhagia.
The Food and Drug Administration has approved Lysteda, a proprietary form of tranexamic acid, for the treatment of menorrhagia.